Growth – Talk Bio

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

2 weeks ago talkbio0Tagged Automation, Cells, digital solutions, gene therapy, Growth, Logistics, Market, patient-specific therapies, risk mitigation, scalability, supply chain, white glove delivery

cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth

Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward

2 months ago talkbio0Tagged earnings, Francis, Growth, operating profit margin, pharmaceutical tariffs, Pivot Device, Richard, supply chain, tariff threat, Teva, turnaround strategy

Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin

CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling

2 months ago talkbio0Tagged capsule (pharmacologic), CDMO, commercial, expansion, Growth, Lonza, Manufacturing, profit margin, Sales - occupational activity, Samsung Bio

Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion

Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed

4 months ago talkbio0Tagged Americas, Biopharma, CEO, Chris Boerner, dealmaking, global competitiveness, Growth, innovation, Myers, squibb

Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

4 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Pivotal readouts on deck as Takeda sees stagnant sales this year

4 months ago talkbio0Tagged Growth, JPY, Phase 3, Pivotal, Sales - occupational activity, Takeda

Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY

Biogen says Leqembi sales are improving slowly following lackluster launch

5 months ago talkbio0Tagged Biogen, Eisai, Growth, Improving (qualifier value), Leqembi, Sales - occupational activity, United States Food and Drug Administration

Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)

Mercks Gardasil sales sink further amid China market pressure

5 months ago talkbio0Tagged China, Gardasil, Gardasil sales, Growth, Market, Pressure- physical agent

Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China

J&J brushes off tariff headwinds with raised forecast, oncology surge

5 months ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Hims eyes growth in its weight loss business, despite end of semaglutide shortage

7 months ago talkbio0Tagged Growth, Hims, semaglutide, United States Food and Drug Administration, weight loss business

semaglutide, weight loss business, United States Food and Drug Administration, Growth, Hims